Author

E. Gogola

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:cell type annotation· 2 Assay:DNA methylation· 2 Research Focus:drug response / drug discovery· 2 Approach:mechanistic / dynamical model· 2 Organism:mouse· 2 Assay:bulk RNA-seq· 1

Frequent Co-Authors

J. Jonkers· 3 shared S. Rottenberg· 3 shared A. Duarte· 2 shared C. Lieftink· 2 shared J. Bhin· 2 shared M. Paes Dias· 2 shared R. L. Beijersbergen· 2 shared A. A. Sartori· 1 shared

Activity by Year

2021-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 34 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

J. Jonkers

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

H2AX promotes replication fork degradation and chemosensitivity in BRCA-deficient tumours

D. Dibitetto, M. Liptay, F. Vivalda, E. Gogola, H. Dogan, M. G. Fernandez, A. Duarte, J. A. Schmid, S. T. Durant, J. V. Forment, I. Klebic, M. Siffert, R. de Brujin, A. N. Kousholt, N. A. Marti, , S. Rottenberg

This study identifies H2AX's role in promoting replication fork degradation and chemosensitivity in BRCA-deficient tumours, independent of its classical DNA damage signalling function.

bioRxiv · May 22, 2023Cancer Biology

Multi-omics analysis reveals distinct non-reversion mechanisms of PARPi resistance in BRCA1- versus BRCA2-deficient mammary tumors

J. Bhin, M. Paes Dias, E. Gogola, F. Rolfs, S. R. Piersma, R. de Bruijn, J. de Ruiter, B. van den Broek, A. Duarte, W. Sol, I. van der Heijden, L. Bakker, T. S. Kaiponen, C. Lieftink, B. Morris, , J. Jonkers

bioRxiv · Sep 7, 2022Cancer Biology

Loss of Nuclear DNA Ligase III Reverts PARP Inhibitor Resistance in BRCA1/53BP1 Double-deficient Cells by Exposing ssDNA Gaps

M. Paes Dias, V. Tripathi, I. v. d. Heijden, K. Cong, E.-M. Manolika, J. Bhin, E. Gogola, P. Galanos, S. Annunziato, C. Lieftink, M. Andujar-Sanchez, S. Chakrabarty, G. C. M. Smith, M. v. d. Ven, R. L. Beijersbergen, , J. Jonkers

This study identifies loss of LIG3 as a factor that reverts PARP inhibitor resistance in BRCA1/53BP1 double-deficient cells by increasing ssDNA gaps.

bioRxiv · Mar 24, 2021 · PreprintCancer Biology